ENTA - Company ID 0001177648
The table below shows ENANTA PHARMACEUTICALS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $17.16M | $18.61M | $18.31M | $14.93M | $16.96M | $17.97M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $19.44M | $20.86M | $27.21M | $28.07M | $27.66M | $28.74M |
ENANTA PHARMACEUTICALS INC reported annual revenue of $65.32M for fiscal year 2025. That is down 3.4% from $67.64M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $88.27M (FY 2016) to $65.32M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $9.57M |
| $9.01M |
| $10.00M |
| $11.39M |
| $12.85M |
| $13.41M |
| Operating income | -$11.85M | -$11.25M | -$18.89M | -$24.53M | -$23.54M | -$24.18M |
| Income tax | $7.00K | $24.00K | $29.00K | -$1.30M | -$416.00K | -$395.00K |
| Net income | -$13.09M | -$11.94M | -$18.25M | -$22.64M | -$22.29M | -$22.66M |
| EPS (diluted) | -$0.45 | -$0.42 | -$0.85 | -$1.06 | -$1.05 | -$1.07 |